Literature DB >> 18059365

Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.

Yunqing Li1, Fadila Guessous, Elizabeth B Johnson, Charles G Eberhart, Xiao-Nan Li, Qing Shu, Shongshan Fan, Bachchu Lal, John Laterra, David Schiff, Roger Abounader.   

Abstract

The growth factor hepatocyte growth factor (HGF), also known as scatter factor, and its tyrosine kinase receptor c-Met play important roles in medulloblastoma malignancy. The transcription factor c-Myc is another contributor to the malignancy of these most common pediatric brain tumors. In the present study, we observed strong morphological similarities between medulloblastoma xenografts overexpressing HGF and medulloblastoma xenografts overexpressing c-Myc. We therefore hypothesized a biologically significant link between HGF/c-Met and c-Myc in medulloblastoma malignancy and studied the molecular and functional interactions between them. We found that HGF induces c-Myc mRNA and protein in established and primary medulloblastoma cells. HGF regulated c-Myc levels via transcriptional and post-transcriptional mechanisms as evidenced by HGF induction of c-Myc promoter activity and induction of c-Myc protein levels in the setting of inhibited transcription and translation. We also found that HGF induces cell cycle progression, cell proliferation, apoptosis and increase in cell size in a c-Myc-dependent manner. Activation of MAPK and PI3K, inhibition of GSK-3beta and translocation of beta-catenin to the nucleus as well as Tcf/Lef transcriptional activity were involved in mediating c-Myc induction by HGF. Induction of Cdk2 kinase activity was involved in mediating the cell cycle progression effects, and downregulation of Bcl-XL was involved in mediating the proapoptotic effects of HGF downstream of c-Myc. All molecules that mediated the effects of HGF on c-Myc expression, cell proliferation and apoptosis were expressed in human large-cell medulloblastoma tissues. We therefore established for the first time a functional cooperation between HGF/c-Met and c-Myc in human medulloblastoma and elucidated the molecular mechanisms of this cooperation. The findings provide a potential explanation for the high frequency of c-Myc overexpression in medulloblastoma and suggest a cooperative role for c-Met and c-Myc in large-cell anaplastic medulloblastoma formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059365     DOI: 10.1038/labinvest.3700702

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

Review 1.  Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Authors:  Jasmine Lau; Christin Schmidt; Shirley L Markant; Michael D Taylor; Robert J Wechsler-Reya; William A Weiss
Journal:  Childs Nerv Syst       Date:  2012-04       Impact factor: 1.475

Review 2.  Childhood medulloblastoma: current status of biology and treatment.

Authors:  Laura J Klesse; Daniel C Bowers
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

3.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

4.  MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway.

Authors:  Yanzhi Yang; Samantha Dodbele; Thomas Park; Rainer Glass; Krishna Bhat; Erik P Sulman; Ying Zhang; Roger Abounader
Journal:  J Neurooncol       Date:  2019-09-03       Impact factor: 4.130

5.  Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.

Authors:  Fadila Guessous; Yanzhi Yang; Elizabeth Johnson; Lukasz Marcinkiewicz; Matthew Smith; Ying Zhang; Alexander Kofman; David Schiff; James Christensen; Roger Abounader
Journal:  Mol Cancer Ther       Date:  2011-12-21       Impact factor: 6.261

6.  Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Authors:  Ying Zhang; Kaitlyn E Farenholtz; Yanzhi Yang; Fadila Guessous; Charles G Dipierro; Valerie S Calvert; Jianghong Deng; David Schiff; Wenjun Xin; Jae K Lee; Benjamin Purow; James Christensen; Emanuel Petricoin; Roger Abounader
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

7.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 8.  A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention.

Authors:  Allen Y Chen; Yi Charlie Chen
Journal:  Food Chem       Date:  2012-12-28       Impact factor: 7.514

9.  Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells.

Authors:  Mathieu Provençal; Nancy Berger-Thibault; David Labbé; Ryan Veitch; Dominique Boivin; Georges-Etienne Rivard; Denis Gingras; Richard Béliveau
Journal:  J Neurooncol       Date:  2009-11-18       Impact factor: 4.130

10.  microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.

Authors:  Jungeun Kim; Ying Zhang; Michael Skalski; Josie Hayes; Benjamin Kefas; David Schiff; Benjamin Purow; Sarah Parsons; Sean Lawler; Roger Abounader
Journal:  Cancer Res       Date:  2014-01-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.